Tag: Paris:IPN

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx^® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

Aggregated presentation by day and by market

Monthly information relative to the total number of voting rights
and shares composing the share capital

Information mensuelle relative au nombre total des droits de vote
et d’actions composant le capital social

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF

PARIS, FRANCE, 2 JUILLET 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) inaugure aujourd’hui son nouveau siège social dans le 15ème arrondissement de Paris au 70, rue Balard. Le bâtiment, entièrement rénové pour accueillir le siège mondial d’Ipsen, s’étend sur une superficie totale de 9 500 m² répartis sur 7 étages (hors rez-de-chaussée) et accueille 600 postes de travail individuels.

 Aggregated presentation by day and by market

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

Aggregated presentation by day and by market